The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LVIII.a

Path: NSIP-cellular pattern (see also Ia, Ib)

Publications

Saito Y, Kunugi S, Suzuki Y, Narita K, Miura Y, Minegishi Y, Kimura G, Kondo Y, Azuma A, Fukuda Y, Gemma A

Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.

Internal medicine (Tokyo, Japan) 2013;52;263-7 — 2013 — 263-7

Su?kowska K, Palczewski P, Miszewska-Szyszkowska D, Durlik M, Go??biowski M, Ma?kowski P

Early everolimus-induced pneumonitis in a renal transplant recipient: A case report.

Annals of transplantation 2012 Dec 31;17;144-8 — 2012 Dec 31 — 144-8

Mizuno R, Asano K, Mikami S, Nagata H, Kaneko G, Oya M

Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.

Japanese journal of clinical oncology 2012 May;42;442-6 — 2012 May — 442-6

Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L

Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.

Transplant international : official journal of the European Society for Organ Transplantation 2010 Jan;23;110-3 — 2010 Jan — 110-3